A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

作者：Fazio Nicola^*; Buzzoni Roberto; Baudin Eric; Antonuzzo Lorenzo; Hubner Richard A; Lahner Harald; De Herder Wouter W; Raderer Markus; Teule Alexandre; Capdevila Jaume; Libutti Steven K; Kulke Matthew H; Shah Manisha; Dey Debarshi; Turri Sabine; Aimone Paola; Massacesi Cristian; Verslype Chris

来源：Anticancer Research, 2016, 36(2): 713-719.

• BEZ235
• everolimus
• mTOR
• PI3K
• pNETs

Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of >= 60% in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2.

• 出版日期2016-2